SEC Form 6-K Summary
Business Context and Reporting Period
NLS Pharmaceutics Ltd., a Swiss foreign private issuer, filed Form 6-K on November 18, 2021, for the month of November 2021 (Report No. 2). The filing concerns an extraordinary shareholders’ meeting scheduled for December 10, 2021.
The provided request metadata identifies the company as Newcelx Ltd.; however, the filing itself identifies the registrant as NLS Pharmaceutics Ltd. This discrepancy should be verified.
Financial Metrics
The filing does not provide financial statements or clear values for revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
The filing reports no operating or financial changes. Its contents consist of the notice of meeting and proxy card for the extraordinary shareholders’ meeting, filed as Exhibit 99.1.
Meeting, Outlook, and Risks
- The extraordinary shareholders’ meeting is scheduled for December 10, 2021.
- Only shareholders of record holding common shares at the close of business on November 8, 2021, are entitled to vote at the meeting and any postponement or adjournment.
- The filing does not state the specific proposals to be voted on; those details are contained in the referenced Notice of Meeting and Proxy Card.
- No guidance, management outlook, contingencies, or unusual financial items are disclosed in the provided filing text.
Key Facts to Verify
- Confirm whether the correct registrant is NLS Pharmaceutics Ltd. or Newcelx Ltd.
- Review Exhibit 99.1 for the meeting agenda, proposed resolutions, and proxy voting instructions.
- Confirm the November 8, 2021 record date and December 10, 2021 meeting date.
- Determine whether subsequent filings disclose the meeting results or any resulting corporate actions.